Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAST: High-dose Ranibizumab in AMD
NCT01115556Phase 2Completed
- Sponsor
- Vitreous Retina Macula Consultants of New York
- Start
- May 2010
- Primary completion
- Jan 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of ranibizumab in age-related macular degeneration (AMD) (2 arms), sponsored by Vitreous Retina Macula Consultants of New York. Primary endpoint: Visual Acuity at 6 months. Started May 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT01115556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01115556.